Trials / Completed
CompletedNCT02384512
Azilect® In Wearing-Off (AIWO)
Azilect® In Wearing-Off (AIWO) Non-interventional Study on Efficacy and Tolerability of Rasagiline (1mg/d) add-on in Ambulatory Parkinson's Disease Patients With Wearing-off Symptoms Diagnosed by Wearing-off Questionnaire (WOQ-32)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 261 (actual)
- Sponsor
- Teva Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
End-of-dose fluctuations e. g. wearing-off are defined as a recurrence of motor and non-motor Parkinson's Disease (PD) symptoms that precedes a scheduled dose and improves with the next dose of anti-parkinsonian medication. Azilect® is approved and recommended for therapy of wearing-off-/End-of-dose fluctuations and improves motor fluctuations significantly in combination therapy with L-dopa and other parkinsonian medication.
Detailed description
The aim of the non-interventional study is to document efficacy and tolerability of rasagiline as a combination therapy in patients with wearing-off-/End-of-dose fluctuations and the effect of rasagiline on individual wearing-off symptoms, recognized by wearing-off questionnaire 32 (WOQ-32).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azilect® | AZILECT® 1mg Tablets |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-12-01
- Completion
- 2015-01-01
- First posted
- 2015-03-10
- Last updated
- 2023-04-12
Locations
140 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02384512. Inclusion in this directory is not an endorsement.